In patients with peripheral artery disease undergoing revascularization, major adverse limb events were more common with ...

Peripheral Artery Revascularization Market has been evolving and changing over the course of past few decades and the market scope has changed a lot over the course of time and to better understand ...

Please provide your email address to receive an email when new articles are posted on . Among patients with peripheral artery disease, the use of vorapaxar appears to reduce peripheral ...

More than 80% of no-option chronic limb-threatening ischemia patients avoided amputation for 6 months after the procedure ...

October 9, 2009 (Vienna, Austria) — A reduction in major amputations associated with diabetic foot followed the increased rates of peripheral revascularization that occurred after implementation of ...

Both the incidence and degree of bleeding events after peripheral revascularization match what’s seen for coronary revascularization and for lower-extremity amputation, new findings from the EUCLID ...

Artificial intelligence shows promise for improving care for peripheral artery disease through earlier detection, improved ...

In the Losartan Intervention For End point reduction in hypertension (LIFE) study losartan- compared to atenolol-based antihypertensive treatment showed a tendency towards reducing peripheral ...

People who took rivaroxaban (Xarelto) after lower-extremity revascularization for peripheral artery disease (PAD) enjoyed fewer subsequent major adverse limb and cardiovascular events, according to ...

A substantial proportion of patients with stable claudication continue to smoke and do not receive aspirin or statin therapy before undergoing endovascular treatment, according to registry findings ...

Lower extremity artery disease (LEAD) is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions of people. On top of that, LEAD also represents a prominent marker of ...